Five Days Quadruple and Clarithromycin Containing Triple Therapy as Treatment for Helicobacter Pylori Eradication

• Status: Completed
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this randomized trial is to compare the efficacy and tolerability of H. pylori eradication with a 5-day quadruple therapy versus a clarithromycin-containing triple therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Hong Kong
• Treatments: Amoxicillin; Bismuth; Bismuth tripotassium dicitrate; Clarithromycin; Esomeprazole; Metronidazole; Tetracycline

Criteria

Inclusion Criteria:

• patients with H. pylori infection

• did not receive H. pylori eradication therapy before

Exclusion Criteria:

• patients who have received previous H. pylori eradication therapy

• co-morbidity of liver cirrhosis

• co-morbidity of renal failure

• co-morbidity of alcoholism

• co-morbidity of malignancy

• received antibiotics, bismuth preparations, proton pump inhibitors or probiotic in the preceding three months

• patients with known allergy to the medications used

• patients with a history of previous gastrointestinal diseases or gastric surgery

• pregnancy